knowledge -WSS

knowledge

author：leisure time 2025-10-02 23:48:09 - browse：3

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： A public scorecard can help hold safety

WSS

Tori Bowie and the unacceptable rates of Black maternal death

In Memoriam: Notable people who died in 2023

Sports medicine is finally prioritizing gender equality

FDA approves RSV monoclonal antibody for infants, toddlers

Novavax promises a turnaround & Lilly roils the obesity market

Virginia high school admissions case could be legal follow

entertainment

knowledge

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

DIEP, the 'gold standard' of breast reconstruction, is under threat

Alkermes shareholders re

Peter Hotez and the public health issue of online harassment

23andMe had bad news about my health. I wish a person had delivered it

Hepatitis C has a cure — but many Americans still lack access to it

George Santos makes 1st court appearance after pleading not guilty to 13 counts

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

As demand for Covid shots wanes, Moderna seeks its next success

How Medicaid coverage policies for immigrants impact new moms

Wikipedia

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Dobbs anniversary: the lost opportunity of abortion as health care

Custom gene therapy hints at new path for rare disease treatments

Sanders adds drug shortage policies to pandemic preparedness bill

STAT Virtual Event: The State of Biosimilars: What to Watch

Listen: Wegovy in the brain & pivotal Alzheimer's data

leisure time

focus

entertainment

hotspot